tbuckley/cabot-search huggingface dataset:
974TiP Exploratory phase Ib/IIa study of intratumorally administered tigilanol tiglate to assess safety, tolerability and tumour response in patients with head and neck squamous cell carcinoma
Authors: R.M. Gallagher, A. Pattatheyil, G.H. Pantvaidya, B.J. Panizza, R. Sharan, A.D. Deshmukh, C.M.E. Barnett, D.J. Swart, T.L. Mynott, A. Cleal, V. Gordon, A. Prawira
Journal: Annals of Oncology (2020)
1417TiP Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial
Authors: M. Guckenberger, I. Opitz, U. Dafni, A. Curioni Fontecedro, A. Scherz, O. Elicin, A. Addeo, J.G.J.V. Aerts, A-M. Dingemans, L. Hendriks, B. Jimenez Munarriz, O. Juan-Vidal, I. Sullivan, J. Valdivia, A-C. Piguet, H. Roschitzki-Voser, S. Ehrbar, M. Baumgartl, S. Peters, R.A. Stahel
Journal: Annals of Oncology (2020)
1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
Authors: A.M. Di Giacomo, V. Chiarion Sileni, M. Del Vecchio, P.F. Ferrucci, M. Guida, P. Quaglino, M. Guidoboni, P. Marchetti, O. Cutaia, G. Amato, E. Gambale, L. Calabrò, M. Valente, R. Danielli, D. Giannarelli, M. Mandala, M. Maio
Journal: Annals of Oncology (2020)
697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
Authors: T.B. Powles, M.S. van der Heijden, D. Castellano Gauna, Y. Loriot, M.D. Galsky, D.P. Petrylak, O. Ogawa, S.H. Park, A. Necchi, J-L. Lee, U. De Giorgi, M. Bögemann, A. Bamias, A.P. Fay, I. Duran, N. Angra, A.K. Gupta, P. He, W. Levin, J. Bellmunt
Journal: Annals of Oncology (2020)
Oncogene-induced DNA damage: cyclic AMP steps into the ring
Authors: James A. Fagin, John H. Petrini
Journal: Journal of Clinical Investigation (2020)

Growth hormone-secreting (GH-secreting) pituitary tumors are driven by oncogenes that induce cAMP signaling. In this issue of the JCI, Ben-Shlomo et al. performed a whole-exome study of pituitary adenomas. GH-secreting tumors had a high frequency of whole chromosome or chromosome arm copy number alterations and were associated with an increase in the tumor protein p53 and the cyclin-dependent kinase inhibitor p21WAF1/CIP1, which are findings consistent with induction of a response to DNA damage. Further, treatment of mouse pituitary cells with cAMP pathway agonists in vitro and in vivo elicited biomarkers of DNA replication stress or double-strand breaks. The findings of Ben Shlomo et al. indicate that oncoproteins that drive constitutively high cAMP signaling pathway output in susceptible cell types can elicit DNA replication stress and may promote genomic instability.
Effect of asthma and asthma medication on the prognosis of patients with COVID-19
Authors: Yong Jun Choi, Ju-Young Park, Hye Sun Lee, Jin Suh, Jeung Yoon Song, Min Kwang Byun, Jae Hwa Cho, Hyung Jung Kim, Jae-Hyun Lee, Jung-Won Park, Hye Jung Park
Journal: European Respiratory Journal (2020)

Background Coronavirus disease 2019 (COVID-19) has spread worldwide rapidly. However, the effects of asthma, asthma medication and asthma severity on the clinical outcomes of COVID-19 have not yet been established. Methods The study included 7590 de-identified patients, who were confirmed to have COVID-19 using the severe acute respiratory syndrome coronavirus 2 RNA-PCR tests conducted up to May 15, 2020; we used the linked-medical claims data provided by the Health Insurance Review and Assessment Service. Asthma and asthma severity (steps suggested by the Global Initiative for Asthma) were defined using the diagnostic code and history of asthma medication usage. Results Among 7590 COVID-19 patients, 218 (2.9%) had underlying asthma. The total medical cost associated with COVID-19 patients with underlying asthma was significantly higher than that of other patients. Mortality rate for COVID-19 patients with underlying asthma (7.8%) was significantly higher than that of other patients (2.8%; p&lt;0.001). However, asthma was not an independent risk factor for the clinical outcomes of COVID-19 after adjustment, nor did asthma medication use and asthma severity affect the clinical outcomes of COVID-19. However, use of oral short-acting β 2 -agonists was an independent factor to increase the total medical cost burden. Patients with step 5 asthma showed significant prolonged duration of admission compared to those with step 1 asthma in both univariate and multivariate analysis. Conclusions Asthma led to poor outcomes of COVID-19; however, underlying asthma, use of asthma medication and asthma severity were not independent factors for poor clinical outcomes of COVID-19, generally.
207P 10-year real-world outcomes with neoadjuvant systemic therapy in non-inflammatory breast cancer
Authors: A. Kovac, K. Cankar, L. Dobovisek, L. Cavka, E. Godina, V. Jeric Horvat, M. Rajer, T. Starman, E. Matos, S. Borstnar
Journal: Annals of Oncology (2020)
1136P Feasibility of linking the UK 100,000 genomes project and real-world evidence databases for a melanoma patient population
Authors: E. Scherrer, G.M. Hair, S. Mt-Isa, M. Pereira, G. Chan, I. Shui, P. Arumugam, M. Zarowiecki, K. Witkowska, T. Rahim, S. Turajlic, K.R. Litchfield, P. Lorigan, J. Larkin
Journal: Annals of Oncology (2020)
736P Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial
Authors: G. Procopio, F. Cognetti, R. Miceli, M. Milella, A. Mosca, V.E. Chiuri, A. Bearz, F. Morelli, C. Ortega, F. Atzori, M. Donini, R. Passalacqua, A. Mennitto, P. Sepe, A. Martinetti, R. Montone, G. Apollonio, V. Guadalupi, E. Verzoni, M. Claps
Journal: Annals of Oncology (2020)
1899P Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET)
Authors: J.C. Benitez Montanez, M-É. Boucher, E. Dansin, M. Kerjouan, J. Mazieres, E. Pichon, F. Thillays, P.E. Falcoz, B. Roch, Y. Oulkhouir, F. Calcagno, L. Thiberville, C. Clément-Duchêne, F. Morin, P. Missy, P.A. Thomas, J.-M. Maury, T. Molina, N. Girard, B. Besse
Journal: Annals of Oncology (2020)
LBA36 Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET
Authors: A. Oaknin, L. Gilbert, A.V. Tinker, R. Sabatier, V. Boni, D.M. O'Malley, S. Ghamande, L. Duska, P. Ghatage, W. Guo, E. Im, B. Pothuri
Journal: Annals of Oncology (2020)
LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer
Authors: E.L. Mayer, M.I. Gnant, A. DeMichele, M. Martin, H. Burstein, A. Prat, G. Rubovszky, K.D. Miller, G. Pfeiler, E.P. Winer, N. Zdenkowski, D. Anderson, Z. Nowecki, S. Loibl, H. Fohler, O. Metzger, D. Fumagalli, K. Puyana Theall, C. Fesl, A. Dueck
Journal: Annals of Oncology (2020)
342P Different modalities of detection breast cancer recurrences: A 5-year retrospective cohort study
Authors: D. Zara, L. Palmero, G. Targato, M. Giavarra, D. Basile, M.G. Vitale, E. Bertoli, M. Mansutti, M. Bonotto, F. Puglisi, G. Fasola, A.M. Minisini
Journal: Annals of Oncology (2020)
793P CHEK2 inactivating germ-line mutations play a role in the development of testicular cancer
Authors: E. Imyanitov, V. Ni, A.O. Ivantsov, M. Kotkova, S. Baskina, E. Ponomareva, K.V. Shelekhova, A. Romanko, S. Aleksakhina, A.V. Togo, A. Sokolenko
Journal: Annals of Oncology (2020)
1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer
Authors: P. Bono, P. Jaakkola, S. Shetty, Y.T. Ma, M.J.A. de Jonge, D. Robbrecht, A.R. Minchom, A. Pal, C. Yap, A. Pasanen, T. Skytta, A. Thibault, R. Cruz, M. Jalkanen, S. Jalkanen, M. Hollmén, J. Mandelin, M. Karvonen, J. Koivunen
Journal: Annals of Oncology (2020)
CN19 Healthcare professionals' perception about end-of-life conversations: An observational cross-sectional study
Authors: G. Catania, M. Zanini, P. Pilastri, P. Borsellino, L. Forni, C. Guglielmelli, M. Valera, S. Marenco, M. Gallucci, L. Sasso, A. Bagnasco
Journal: Annals of Oncology (2020)
401MO OS and long-term DFS with 3- vs. 6-month adjuvant oxaliplatin and fluoropyrimidine-based therapy for stage III colon cancer patients: A randomized phase III ACHIEVE trial
Authors: T. Yoshino, M. Kotaka, D. Manaka, T. Eto, J. Hasegawa, A. Takagane, M. Nakamura, T. Kato, Y. Munemoto, F. Nakamura, H. Bando, H. Taniguchi, Y. Sakamoto, M. Shiozawa, M. Nishi, T. Horiuchi, T. Mizushima, T. Yamanaka, A. Ohtsu, M. Mori
Journal: Annals of Oncology (2020)
1918P Final analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) for the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)
Authors: M.S. Brose, J.W.A. Smit, C-C. Lin, M. Tori, D.W. Bowles, F. Worden, D.H-Y. Shen, S-M. Huang, M. Alevizaki, R.P. Peeters, S. Takahashi, P. Rumyantsev, R. Guan, S. Babajanyan, K. Ozgurdal, I. Sugitani, F. Pitoia, L. Lamartina
Journal: Annals of Oncology (2020)
1921P Prognostic impact of [18F]FDG-PET/CT in differentiated thyroid cancer with bone metastasis: A French TUTHYREF study
Authors: A. Jannin, L. Lamartina, C. Moutarde, M. Djennaoui, G. Lion, M-C. Vantyghem, S. Leboulleux, C. Do Cao
Journal: Annals of Oncology (2020)
175P Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)–positive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy
Authors: F. Ligorio, L. Zambelli, A. Bottiglieri, L. Castagnoli, E. Zattarin, R. Loberfaro, A. Belfiore, A. Vingiani, G. Pruneri, G. Bianchi, G. Capri, S. Pupa, F. de Braud, C. Vernieri
Journal: Annals of Oncology (2020)
309P Real-world effectiveness of alpelisib (ALP) + fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2–) PIK3CA-mutated (Mut) advanced breast cancer (ABC)
Authors: S. Turner, S.K.L. Chia, H. Kanakamedala, W-C. Hsu, J. Park, D. Chandiwana, A. Ridolfi, C-L. Yu, J.P. Zarate, H.S. Rugo
Journal: Annals of Oncology (2020)
1149P Validation of a model combining clinicopathologic risk factors and a gene expression profile to identify primary melanoma patients who can safely forgo sentinel lymph node biopsy
Authors: A. Meves, A.B. Yousaf, D. Tempel, M. Luna-Vargas, J. Chen, J. Dwarkasing, M.S. Kolodney
Journal: Annals of Oncology (2020)
771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer
Authors: V.S. Koshkin, Y. Sun, C.K. Osterman, D. Natesan, C. Su, E. Lemke, A.R. Khaki, A. Johnson, X. Owens, J.J. Park, A. Basu, P.M. Coelho Barata, N. Davis, P. Grivas, M. Milowsky, D. Kilari, A. Alva
Journal: Annals of Oncology (2020)
1009P Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Authors: H.Y. Lim, Y.J. Kim, Y-H. Huang, G. Shao, D.Y. Kim, S.B. Cho, C-H. Hsu, S-M. Lin, L-B. Jeng, K-K. Kuo, Y. Mao, K. Zhu, Y.M. Hong, H.C. Lee, B-Y. Ryoo, Z. Niu, L. Wu, S. Fiala-Buskies, S. Kapur, S. Qin
Journal: Annals of Oncology (2020)

In the phase III RESORCE trial, regorafenib improved overall survival (OS) vs placebo in pts with uHCC who progressed on sorafenib. The international, prospective REFINE study was designed to evaluate regorafenib in pts with uHCC in routine practice. We present interim results for pts enrolled in REFINE in Korea, China, and Taiwan. REFINE is an ongoing observational study that recruited patients with uHCC for whom a decision to treat with regorafenib was made by the treating physician prior to enrollment according to the local health authority approved label. A planned interim analysis was performed when the first 500 pts in the global cohort had been observed for ≥4 months. The primary aim is to assess treatment-emergent adverse events (TEAEs; NCI-CTCAE v4.03). Secondary endpoints include OS, progression-free survival, and tumor response. Tumor response and progression are assessed per investigator according to local standard. In the interim analysis, a total of 182 pts were enrolled from Korea (n=127; 70%), China (n=48; 26%), and Taiwan (n=7; 4%). The median age was 60 years (range 21–90); 80% were male. At study entry, proportions of pts with ECOG performance status 0/1/≥2 were 37%/49%/5%; proportions with Child–Pugh A/B/C class were 70%/5%/1% (missing/not evaluable: 24%). The initial daily regorafenib dose was 160 mg in 70% of pts and 120 mg/80 mg in 14%/15%; 1 pt started at 40 mg. The mean initial daily dose was 142 mg (standard deviation 31). Median treatment duration was 3.2 months (interquartile range 1.9–9.3). The most frequent TEAEs (reported in ≥5% patients) are shown in the table. Effectiveness results will be presented. In this interim analysis of pts from Asia in the observational REFINE study, the TEAEs reported were consistent with those reported in the phase III RESORCE trial, although incidence rates of some TEAEs were lower than in RESORCE.Table: 1009PTEAE, %Regorafenib (n=182)Any gradeGrade 3Grade 4Hand–foot skin reaction291-Diarrhea1420Decreased appetite910Abdominal pain730Hypertension620Fatigue51- Open table in a new tab
1504O Relationship between sarcopenia and anthracycline related cardiotoxicity in patients with cancer
Authors: O. Bas, A. Erdemir, R. Onur, G. Guner, D.C. Guven, S. Aksu, N. Kertmen, S. Aksoy, I. Barista, A. Turker, O. Dizdar
Journal: Annals of Oncology (2020)
MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
Authors: Hans-Georg Wirsching, Ulrich Roelcke, Jonathan Weller, Thomas Hundsberger, Andreas F. Hottinger, Roger von Moos, Francesca Caparrotti, Katrin Conen, Luca Remonda, Patrick Roth, Adrian Ochsenbein, Ghazaleh Tabatabai, Michael Weller
Journal: Clinical Cancer Research (2020)

To explore a prognostic or predictive role of MRI and O-(2-18F-fluoroethyl)-L-tyrosine (18FET) PET parameters for outcome in the randomized multicenter trial ARTE that compared bevacizumab plus radiotherapy with radiotherpay alone in elderly patients with glioblastoma.Patients with isocitrate dehydrogenase wild-type glioblastoma ages 65 years or older were included in this post hoc analysis. Tumor volumetric and apparent diffusion coefficient (ADC) analyses of serial MRI scans from 67 patients and serial 18FET-PET tumor-to-brain intensity ratios (TBRs) from 31 patients were analyzed blinded for treatment arm and outcome. Multivariate Cox regression analysis was done to account for established prognostic factors and treatment arm.Overall survival benefit from bevacizumab plus radiotherapy compared with radiotherapy alone was observed for larger pretreatment MRI contrast-enhancing tumor [HR per cm3 0.94; 95% confidence interval (CI), 0.89-0.99] and for higher ADC (HR 0.18; CI, 0.05-0.66). Higher 18FET-TBR on pretreatment PET scans was associated with inferior overall survival in both arms. Response assessed by standard MRI-based Response Assessment in Neuro-Oncology criteria was associated with overall survival in the bevacizumab plus radiotherapy arm by trend only (P = 0.09). High 18FET-TBR of noncontrast-enhancing tumor portions during bevacizumab therapy was associated with inferior overall survival on multivariate analysis (HR 5.97; CI, 1.16-30.8).Large pretreatment contrast-enhancing tumor mass and higher ADCs identify patients who may experience a survival benefit from bevacizumab plus radiotherapy. Persistent 18FET-PET signal of no longer contrast-enhancing tumor after concomitant bevacizumab plus radiotherapy suggests pseudoresponse and predicts poor outcome.
1196P Identification of targetable alterations using NGS-based liquid biopsy in NSCLC patients
Authors: A. Moreno-Manuel, S. Gallach Garcia, S. Calabuig-Fariñas, A. Blasco Cordellat, M. Ferrero Gimeno, V. Ruiz Cordero, S. Torres Martinez, E. Duréndez, M. Mosqueda, E. Escorihuela, A. Fernandez Diaz, F.D.A. Aparisi Aparisi, E. Jantus Lewintre, C. Camps
Journal: Annals of Oncology (2020)
1672MO "DOMONCOVID PROJECT": A homecare model for cancer patients during COVID-19
Authors: M. Ratti, G. Grizzi, M. Bonomi, R. Marchi, F. Negri, B. Perrucci, M.O. Giganti, S. Panni, G. Donati, M. Donini, C. Foroni, A. Gobbi, F. Barbin, F. Gerevini, A. Curti, B. Ferrari, J. Saleri, R. Passalacqua
Journal: Annals of Oncology (2020)
Effect of Escalating and Deescalating Financial Incentives vs Usual Care to Improve Antidepressant Adherence
Authors: Steven C. Marcus, Megan E. Reilly, Kelly Zentgraf, Kevin G. Volpp, Mark Olfson
Journal: JAMA Psychiatry (2020)

This pilot randomized clinical trial examines whether giving a financial incentive in an escalating or deescalating pattern (vs no incentive) to patients receiving antidepressants can enhance medication adherence.
Tobacco smoking induces metabolic reprogramming of renal cell carcinoma
Authors: James Reigle, Dina Secic, Jacek Biesiada, Collin Wetzel, Behrouz Shamsaei, Johnson Chu, Yuanwei Zang, Xiang Zhang, Nicholas J. Talbot, Megan E. Bischoff, Yongzhen Zhang, Charuhas V. Thakar, Krishnanath Gaitonde, Abhinav Sidana, Hai Bui, John T. Cunningham, Qing Zhang, Laura S. Schmidt, W. Marston Linehan, Mario Medvedovic, David R. Plas, Julio A. Landero Figueroa, Jarek Meller, Maria F. Czyzyk-Krzeska
Journal: Journal of Clinical Investigation (2020)

BACKGROUNDClear cell renal cell carcinoma (ccRCC) is the most common histologically defined renal cancer. However, it is not a uniform disease and includes several genetic subtypes with different prognoses. ccRCC is also characterized by distinctive metabolic reprogramming. Tobacco smoking (TS) is an established risk factor for ccRCC, with unknown effects on tumor pathobiology.METHODSWe investigated the landscape of ccRCCs and paired normal kidney tissues using integrated transcriptomic, metabolomic, and metallomic approaches in a cohort of white males who were long-term current smokers (LTS) or were never smokers (NS).RESULTSAll 3 Omics domains consistently identified a distinct metabolic subtype of ccRCCs in LTS, characterized by activation of oxidative phosphorylation (OXPHOS) coupled with reprogramming of the malate-aspartate shuttle and metabolism of aspartate, glutamate, glutamine, and histidine. Cadmium, copper, and inorganic arsenic accumulated in LTS tumors, showing redistribution among intracellular pools, including relocation of copper into the cytochrome c oxidase complex. A gene expression signature based on the LTS metabolic subtype provided prognostic stratification of The Cancer Genome Atlas ccRCC tumors that was independent of genomic alterations.CONCLUSIONThe work identified the TS-related metabolic subtype of ccRCC with vulnerabilities that can be exploited for precision medicine approaches targeting metabolic pathways. The results provided rationale for the development of metabolic biomarkers with diagnostic and prognostic applications using evaluation of OXPHOS status. The metallomic analysis revealed the role of disrupted metal homeostasis in ccRCC, highlighting the importance of studying effects of metals from e-cigarettes and environmental exposures.FUNDINGDepartment of Defense, Veteran Administration, NIH, ACS, and University of Cincinnati Cancer Institute.
727P Cabozantinib (Cabo) concentration (Cmin) association with toxicity (tox) and treatment failure in metastatic renal cell carcinoma (mRCC) patients: The MONICA study
Authors: L. Cerbone, D. Combarel, A. Geraud, S. Foulon, Carolina Alves Costa Silva, E. Colomba-Blameble, L. Derosa, A. Guida, R. Flippot, L. Carril-Ajuria, O. Mir, B. Escudier, A. Paci, L. Albiges
Journal: Annals of Oncology (2020)
950P Prognostic and predictive value of skeletal muscle mass (SMM) in squamous cell carcinoma of the head and neck (SCCHN) in patients treated with immune checkpoint inhibitors (ICI)
Authors: L. Arribas, M. Plana, M. Sospedra, N. Vilariño, M. Taberna Sanz, R. Mesia Nin
Journal: Annals of Oncology (2020)
1991P Detection of PIK3CA mutations in plasma samples at Peruvian Cancer Institute
Authors: M. Galvez-Nino, K. Roque, L. Bernabe, M. Castillo Garcia, J. Sanchez, G.G. Calderon Valencia, M. De la Cruz, J.E. Abugattas, J. Cotrina, H. Guerra, S.P. Neciosup, H.L. Gomez Moreno, C. Castaneda Altamirano
Journal: Annals of Oncology (2020)
Changing Age Distribution of the COVID-19 Pandemic — United States, May–August 2020
Authors: Tegan K. Boehmer, Jourdan DeVies, Elise Caruso, Katharina L. van Santen, Shichao Tang, Carla L. Black, Kathleen P. Hartnett, Aaron Kite-Powell, Stephanie Dietz, Matthew Lozier, Adi V. Gundlapalli
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

the coronavirus disease 2019 (COVID-19) pandemic had resulted in more than 6,800,000 reported U.S. cases and more than 199,000 associated deaths.*Early in the pandemic, COVID-19 incidence was highest among older adults (1).CDC examined the changing age distribution of the COVID-19 pandemic in the United States during May-August by assessing three indicators: COVID-19like illness-related emergency department (ED) visits, positive reverse transcription-polymerase chain reaction (RT-PCR) test results for SARS-CoV-2, the virus that causes COVID-19, and confirmed COVID-19 cases.Nationwide, the median age of COVID-19 cases declined from 46 years in May to 37 years in July and 38 in August.Similar patterns were seen for COVID-19-like illness-related ED visits and positive SARS-CoV-2 RT-PCR test results in all U.S. Census regions.During June-August, COVID-19 incidence was highest in persons aged 20-29 years, who accounted for >20% of all confirmed cases.The southern United States experienced regional outbreaks of COVID-19 in June.In these regions, increases in the percentage of positive SARS-CoV-2 test results among adults aged 20-39 years preceded increases among adults aged ≥60 years by an average of 8.7 days (range = 4-15 days), suggesting that younger adults likely contributed to community transmission of COVID-19.Given the role of asymptomatic and presymptomatic transmission (2), strict adherence to community mitigation strategies and personal preventive behaviors by younger adults is needed to help reduce their risk for infection and subsequent transmission of SARS-CoV-2 to persons at higher risk for severe illness.CDC examined age trends during May-August for 50 states and the District of Columbia (DC) using three indicators: 1) COVID-19-like illness-related ED visits; 2) positive SARS-CoV-2 RT-PCR test results; and 3) confirmed COVID-19 cases.COVID-19-like illness-related ED visits reported by health facilities to the National Syndromic Surveillance Program (NSSP), † had fever with cough, shortness * https://www.cdc.gov/covid-data-tracker/index.html#trends.
LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis
Authors: T.M. Wise-Draper, A. Desai, A. Elkrief, B.I. Rini, D.B. Flora, D.W. Bowles, D. Shah, D. Rivera, D.B. Johnson, G. Lopes, P. Grivas, M.A. Thompson, S. Peters, N.M. Kuderer, N.L. Nock, P. Grover, X. Li, S. Gulati, T.K. Choueiri, J. Warner
Journal: Annals of Oncology (2020)
1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type
Authors: K. Nakagawa, E. Nadal, E.B. Garon, M. Nishio, T. Seto, N. Yamamoto, K. Park, J-Y. Shih, B. Frimodt-Moller, A.H. Zimmermann, C.M. Visseren-Grul, M. Reck
Journal: Annals of Oncology (2020)
1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations
Authors: H. West, F. Cappuzzo, M. Reck, T. Mok, R.M. Jotte, M. Nishio, E. Kim, S. Morris, G. Shankar, W. Zou, D. Shames, M. McCleland, M.A. Socinski
Journal: Annals of Oncology (2020)